{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:37:22Z","timestamp":1774064242235,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2002,11]]},"DOI":"10.1136\/ard.61.suppl_3.iii61","type":"journal-article","created":{"date-parts":[[2014,10,22]],"date-time":"2014-10-22T19:21:31Z","timestamp":1414005691000},"page":"iii61-iii67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"S3","title":["Building consensus on nomenclature and disease classification for ankylosing spondylitis: results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18\u201319 January 2002"],"prefix":"10.1016","volume":"61","author":[{"given":"J","family":"Braun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Sieper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ard.61.suppl_3.iii61_bib1","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0950-3579(98)80037-X","article-title":"The spondylarthropathies: classification and diagnosis. Do we need new terminologies?","volume":"12","author":"Schumacher","year":"1998","journal-title":"Baillieres Clin Rheumatol"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib2","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/art.1780341003","article-title":"The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy.","volume":"34","author":"Dougados","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib3","first-page":"207","article-title":"Ankylosing spondylitis 1992: from Connor to transgenes.","volume":"22","author":"Arnett","year":"1993","journal-title":"J Ir Coll Physicians Surg"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib4","first-page":"2185","volume":"27","author":"Braun","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G","article-title":"Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors.","volume":"41","author":"Braun","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib6","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/00007632-199504000-00022","article-title":"Historical perspective. Pierre Marie. Pioneer investigator in ankylosing spondylitis.","volume":"20","author":"Benoist","year":"1995","journal-title":"Spine"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1136\/ard.54.8.615","article-title":"Commented glossary for rheumatic spinal diseases, based on pathology","volume":"54","author":"Francois","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib8","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0950-3579(98)80046-0","article-title":"Spondylarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation","volume":"12","author":"Dougados","year":"1998","journal-title":"Baillieres Clin Rheumatol"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib9","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial.","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib11","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib12","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/rheumatology\/38.9.878","article-title":"Defining disease activity in ankylosing spondylitis: is a combination of variables (Bath Ankylosing Spondylitis Disease Activity Index) an appropriate instrument?","volume":"38","author":"Calin","year":"1999","journal-title":"Rheumatology"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib13","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/art.10139","article-title":"A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis.","volume":"46","author":"Maksymowych","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib14","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E","article-title":"Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.","volume":"43","author":"Brandt","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/ard.59.6.428","article-title":"Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor \u03b1 (infliximab) in spondyloarthropathy: an open pilot study.","volume":"59","author":"Van den Bosch","year":"2000","journal-title":"Ann Rheum Dis"},{"issue":"suppl","key":"10.1136\/ard.61.suppl_3.iii61_bib16","first-page":"A222","article-title":"Efficacy of infliximab in severe refractory ankylosing spondylitis (AS). Results of a 6 months follow-up open-label study [abstract].","volume":"44","author":"Breban","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib17","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00002281-200107000-00003","article-title":"Entheses and enthesitis: a histopathologic review and relevance to spondyloarthritides.","volume":"13","author":"Francois","year":"2001","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib18","first-page":"980","article-title":"Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis.","volume":"26","author":"Spoorenberg","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1297-319X(01)00328-1","article-title":"Treatment of spondyloarthropathies. Recent advances and prospects in 2001.","volume":"68","author":"Dougados","year":"2001","journal-title":"Joint Bone Spine"},{"issue":"suppl","key":"10.1136\/ard.61.suppl_3.iii61_bib20","first-page":"3","article-title":"Indications and contraindications for systemic gold therapy.","volume":"156","author":"Schattenkirchner","year":"1984","journal-title":"Wien Klin Wochenschr"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib21","first-page":"2054","article-title":"Oral quinine in anklyosing spondylitis: a randomized placebo controlled double blind crossover trial.","volume":"27","author":"Williamson","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/03009749850154320","article-title":"Therapeutic aspects of spondyloarthropathies \u2013 a review.","volume":"27","author":"Leirisalo-Repo","year":"1998","journal-title":"Scand J Rheumatol"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib23","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/art.1780380507","article-title":"Sulfasalazine in the treatment of spondylarthropathy.","volume":"38","author":"Dougados","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib24","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/art.1780391209","article-title":"Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study.","volume":"39","author":"Clegg","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib25","first-page":"1482","article-title":"Meta-analysis of sulfasalazine in ankylosing spondylitis.","volume":"17","author":"Ferraz","year":"1990","journal-title":"J Rheumatol"},{"issue":"suppl III","key":"10.1136\/ard.61.suppl_3.iii61_bib26","doi-asserted-by":"crossref","first-page":"iii58","DOI":"10.1136\/ard.60.90003.iii58","article-title":"New treatment options in ankylosing spondylitis: a role for anti-TNF-alpha therapy.","volume":"60","author":"Sieper","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib27","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.1780370709","article-title":"Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients.","volume":"37","author":"Braun","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib28","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H","article-title":"Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study.","volume":"44","author":"Marzo-Ortega","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.61.suppl_3.iii61_bib29","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/ard.60.8.750","article-title":"Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNF alpha.","volume":"60","author":"Baeten","year":"2001","journal-title":"Ann Rheum Dis"},{"issue":"suppl I","key":"10.1136\/ard.61.suppl_3.iii61_bib30","doi-asserted-by":"crossref","first-page":"i85","DOI":"10.1136\/ard.59.suppl_1.i85","article-title":"Treatment of spondyloarthropathies with antibodies against tumour necrosis factor \u03b1: first clinical and laboratory experiences.","volume":"59","author":"Braun","year":"2000","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724498713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724498713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.61.suppl_3.iii61","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T08:23:38Z","timestamp":1737361418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724498713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11]]},"references-count":30,"alternative-id":["S0003496724498713"],"URL":"https:\/\/doi.org\/10.1136\/ard.61.suppl_3.iii61","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2002,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Building consensus on nomenclature and disease classification for ankylosing spondylitis: results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18\u201319 January 2002","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.61.suppl_3.iii61","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 Copyright 2002 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}